4.5 Article

Tardive dyskinesia and deficit schizophrenia

期刊

ACTA PSYCHIATRICA SCANDINAVICA
卷 124, 期 5, 页码 357-362

出版社

WILEY-BLACKWELL
DOI: 10.1111/j.1600-0447.2011.01751.x

关键词

schizophrenia; deficit syndrome; tardive dyskinesia; negative symptoms

资金

  1. Eli Lilly
  2. Cephalon
  3. Abbott
  4. Boehringer Ingelheim
  5. Sunovion

向作者/读者索取更多资源

Objective: Despite comparable antipsychotic exposure, some patients experience involuntary movements yet others do not. Negative symptoms have been associated with tardive dyskinesia (TD), but it is not certain whether this is an association with primary negative symptoms or the effects of medications. The aim of the present study was to determine whether patients with deficit schizophrenia (who have primary negative symptoms) are more likely to experience TD than those with non-deficit schizophrenia. Method: In 2006, all the people with a clinical diagnosis of schizophrenia in Nithsdale, Southwest Scotland, were identified using the ' key informant' method. These patients were categorized into those with and without the deficit syndrome and assessed for the presence of TD. Patients were also assessed for akathisia and extrapyramidal side effects. Results: Of the 131 people assessed, 31 were categorized as having deficit schizophrenia (23.7%) and 100 people (76.3%) as non-deficit. There was no difference between the two groups with regard to age, antipsychotic exposure, and duration of illness. There was a significant association between deficit features and TD with an odds ratio = 2.97 [95% CI 1.128-6.88, P = 0.009]. Conclusion: Our findings support the proposal that the pathological process underlying deficit schizophrenia can predispose to the development of TD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据